H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on DCTH stock, giving a Buy rating yesterday.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that indicate strong potential for Delcath Systems’ growth. The company is actively expanding its treatment sites and geographical reach, with recent activations signaling robust adoption of their HEPZATO treatment. The goal to have 30 active centers by the end of 2025, along with the expansion of sales regions and an increase in the commercial team, supports the company’s growth trajectory.
Additionally, Delcath’s financial performance shows promise, with a significant increase in revenue and a projection of further revenue growth in the coming years. The completion of enrollment in the Phase 2 CHOPIN study and plans for additional Phase 2 studies in metastatic colorectal cancer and metastatic breast cancer highlight the company’s ongoing commitment to advancing its clinical pipeline. The raised price target to $24, based on a risk-adjusted net present value analysis, further underscores the positive outlook for Delcath Systems, despite inherent commercial, clinical, and regulatory risks.
According to TipRanks, Ramakanth is a 3-star analyst with an average return of 3.1% and a 34.47% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, AbSci, and Ocugen.